New York, NY -- (SBWire) -- 08/05/2019 --It evaluates the data gathered to give an extensive view of the trends of the industry and predicts the possible developments in the forecasted duration. For this study, the historical data has been collected from the years 2016 and 2017 while taking 2018 as the base year to estimate the rise of the industry in the years 2019 to 2026.
Request for FREE sample copy of this premium report at: https://www.reportsanddata.com/sample-enquiry-form/1626
Under the trade name of Ibrane, Palbociclib is a drug used for the treatment of HR-positive, HER2-negative and Metastatic breast treatment. Palbociclib was developed by Pfizer Inc., is an inhibitor of the cyclin-dependent kinases CDK4 and CDK6. HR-positive cancer means that the cancer cells grow in response to the hormones- estrogen and progesterone. HER2 helps in controlling cell growth in case of normal cells, which means that HER2 negative cancer cells may grow slowly and are less likely to come back or spread to other parts of the body. Metastatic breast cancer is cancer which starts at the breast and spreads to the rest of the body parts. Women above the age of 65 are more likely to diagnosed with breast cancer and only a few percentages of cases occur among women younger than 45. Palbociclib is to be taken orally with a cycle of 21 days with food and 7 days without food and is prescribed as a combination therapeutics with either letrozole or fulvestrant.
The global breast cancer drugs market is expected to grow with a CAGR of about 11% during the forecast period of which Palbociclib will hold a significant portion. In 2018, a study presented by International Agency for Research on Cancer (IARC) was published by the World Health Organization (WHO) stated that breast cancer the fifth leading cause of death among women with a death toll of more than 600,000 every year. The prevalence of the diseases and the addition of therapeutics with Palbociclib drug are most likely to contribute towards the growth of the marketplace in the coming years. CDK4 and HER2 inhibitors are the most lucrative segments. The CDK4 inhibitor drugs such as Palbociclib is expected to grow the fastest during the forecast period. The high number of patients, the expiry of patients and the side effects associated with it are its restraints.
The side effects include neutropenia (abnormally low number of white blood cells) which results in a weak immune system, followed by the rise in the risk of infection. Other possible side effects include Leukopenia, anemia, fatigue, diarrhoea, vomiting and more. Nonetheless, the rapidly growing regions such as Latin America and the Asia Pacific are expected to continue driving the growth to the increase in demand. The presence of key players along with well-established R&D infrastructure and the awareness is contributing towards the growth of the market in North America. Increasing R&D investments, a growing number of product approvals, the transition to palbociclib as a primary line of treatment, awareness initiatives, collaborations, are some of the additional factors which will overall have a good impact on the Palbociclib production.
Some of the key findings from our Palbociclib market forecast report
The report provides an analysis of the Palbociclib industry to predict its prospects. The past data is considered from the years 2016 and 2017 while taking 2018 as the base year to estimate the trends in the years 2019 to 2026. The industry has been categorized into different segments based on the product as 75mg Tablets, 100mg Tablets, 125mg Tablets, based on Application as Estrogen Receptor Positive (ER+) Breast Cancer, HER2 Negative (HER2-) Advanced Breast Cancer, Metastatic Breast Cancer, and others to assess their size, share, demand, trends, gross profit, total earnings, revenue and speculate their further aspects.
The data provided here also evaluates the competition in the business to derive the individual placements of the key players in the global sector. The data outlines those sectors of the industry that are expected to undergo substantial developments in the predicted years to aid the readers in deciphering the most profitable ones for their business. By doing so, it also highlights the future areas of the industry that exhibit significant potential for investment.
Make an inquiry before buying this report at: https://www.reportsanddata.com/make-enquiry-form/1626
Global Palbociclib Market overview
The global Palbociclib industry is expected to grow steadily in the upcoming years. Asia Pacific is anticipated to expand at the fastest CAGR of 12% during the forecast period. The other geographical regions covered in this study are Europe, North America, Latin America, Middle East and Africa. The key players in the Palbociclib drug businesses are Pfizer, Beacon Pharmaceuticals, Incepta Pharmaceuticals, Bluepharma, NANO DARU, among others. The data here offers an all-encompassing outlook of the global landscape of Bisphenol A (BPA) marketplace to guide the investors in making well-informed executive decisions.
Key players in the global Palbociclib market:
- Pfizer
- Beacon Pharmaceuticals
- Incepta Pharmaceuticals
- Bluepharma
- NANO DARU
Market segment based on product:
- 5mg Tablets
- 100mg Tablets
- 125mg Tablets
Market segment based on application:
- Estrogen Receptor Positive (ER+) Breast Bancer
- HER2 Negative (HER2-) Advanced Breast Cancer
- Metastatic Breast Cancer
Market segment by Region/Country include:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Browse full report description @ https://www.reportsanddata.com/report-detail/palbociclib-market
About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.
Contact Us:
John Watson
Head of Business Development
E-mail: sales@reportsanddata.com
Direct Line: +1-212-710-1370
Reports and Data | Web: www.reportsanddata.com
News: www.reportsanddata.com/market-news
Palbociclib Market Growth, Trends and Forecast to 2026: Top Key Players Are Bluepharma, NANO DARU, Pfizer, Beacon Pharmaceuticals